SynthesisFrontiers in public health2025
Epidemiological trends and determinants of mumps outbreaks: a systematic review and meta-analysis.
Synthesis in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Mumps resurgence despite MMR: Limitations of current vaccines and the need for new strategies.Human vaccines & immunotherapeutics · 2026Review
- Seroprevalence of IgG Antibodies to Measles, Mumps, Rubella and Varicella in Adolescents with Documented Two-Dose MMR Vaccination: Cross-Sectional Study.Antibodies (Basel, Switzerland) · 2026Article
- Recurrent Mumps in a Fully Vaccinated Young Adult With a Prior Breakthrough Infection: A Case Report.Cureus · 2026Article
- Age- and Sex-Dependent Heterogeneity in Mumps Virus Immunity Among US Blood Donors Born Between 1928-1993.The Journal of infectious diseases · 2026Article
- Completeness of MMR Vaccination and Durability of Vaccine-Induced Antibody Responses in Children with Inflammatory Bowel Disease.Biomedicines · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Despite widespread vaccination programs, mumps has resurged globally. This systematic review and meta-analysis assessed the epidemiological characteristics, attack rates (ARs), and complications of mumps outbreaks worldwide from 2004 to 2024. Methods: We systematically searched MEDLINE, Embase, CINAHL and Google Scholar for studies reporting on mumps outbreaks. Confirmed mumps cases, defined by WHO criteria, were included across all age groups. Epidemiological characteristics were summarized using the Time-Place-Person format. Pooled ARs and complication rates were calculated using random-effects models. Subgroup analyses examined variations by age, region, vaccination status, and outbreak period. A random-effects meta-regression and leave one out sensitivity analysis was used to explore the influence of study-level characteristics heterogeneity in the attack rate among mumps outbreak studies. Heterogeneity was assessed using Cochran's Q and I Results: A total of 47 studies from 21 countries reporting 71,174 mumps cases, were included in the systematic review, with 30 studies in the meta-analysis. The pooled AR of mumps outbreaks was 14.5% (95% CI: 12.91-16.11), with adults having the highest AR (31.8%). The pooled complication rate was 10.3% (95% CI: 5.7-14.9), with orchitis being the most common complication (63.1%). Temporal trends showed peaks during 2004-2009 and 2016-2020, while regional analysis revealed higher ARs in the Americas (29.2%) and Eastern Mediterranean (28.8%) regions compared to Europe (7.6%) and South-East Asia (9.6%). Among vaccinated individuals, ARs were highest with a single dose (35.7%) and lowest with three doses (10.1%). Conclusion: Mumps outbreaks remain a global concern due to waning vaccine-induced immunity. Incorporating a third MMR booster dose into vaccination schedules is recommended, particularly for high-risk groups, to reduce ARs and complications effectively. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.